Form D · Other

Nautilus Biotechnology, Inc.

San Carlos, CA · CIK 0001741638

Offering snapshot reported May 28, 2020 · SEC filing

Reported sold
$76.1M
Offering amount: $76.1M
Investors reported
19
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Apr 8, 2020
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$38M$76.1MApr 22, 2020: $0.00Apr 22, 2020May 28, 2020: $76,059,938.00May 28, 2020

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$0 → $76,059,938
  • Reported investors14 → 19

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 28, 2020Amendment$76,059,938$76,059,938vs Apr 22, 202019SEC filing
Apr 22, 2020Initial$0No comparison14SEC filing
May 30, 2018Initial$27,199,972No comparison11SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-365575

Source: Form D, filed May 28, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Parag Mallick Director
Stuart Nagae Director
Farzad Nazem Director
Vijay Pande Director
Sujal Patel Director, Executive
Matthew Posard Director

Issuer details

Industry: Other (See others in industry)

Address:
201 Industrial Rd., Ste 310
San Carlos, CA, 94070